A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

This trial is testing a targeted drug called sotorasib — given before surgery — in combination with standard chemotherapy drugs (cisplatin or carboplatin plus pemetrexed) for people with early-stage non-small cell lung cancer that has a specific mutation called KRAS G12C. Sotorasib works by directly blocking the KRAS G12C protein that drives cancer growth. Giving it before surgery (neoadjuvant therapy) may shrink the tumor and improve surgical outcomes. **You may be eligible if...** - You are over 18 with confirmed non-squamous non-small cell lung cancer (e.g., adenocarcinoma) - Your tumor has a KRAS G12C mutation confirmed by testing - Your cancer is stage IIA to IIIB and considered surgically removable - You have not had prior treatment for this lung cancer - You are in adequate health to tolerate surgery and chemotherapy **You may NOT be eligible if...** - Your tumor is pure squamous cell carcinoma, neuroendocrine carcinoma, small-cell type, or sarcomatoid carcinoma - You have had previous systemic treatment for this cancer - You have uncontrolled infection, severe organ dysfunction, or cannot take the oral medication - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.